{"id":3597086,"date":"2022-04-14T06:45:00","date_gmt":"2022-04-14T10:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/"},"modified":"2025-03-07T23:39:57","modified_gmt":"2025-03-08T04:39:57","slug":"merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/","title":{"rendered":"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults"},"content":{"rendered":"<div class=\"q4default\">\n<p class=\"bwalignc\">\n  <b>V116 Designed to Target Serotypes that Account for 85% of all Invasive Pneumococcal Disease in Individuals Aged 65 and Over in the United States as of 2019<sup>1<\/sup><\/b>\n<\/p>\n<p class=\"bwalignc\">\n  <b>Phase 3 Clinical Trials for V116 to be Initiated in 2022<\/b>\n<\/p>\n<p>    KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211;<br \/>\nMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that V116, the company\u2019s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by <i>Streptococcus pneumoniae <\/i>serotypes 3, 6A\/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B\/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 clinical trials for V116 are to be initiated later this year.\n<\/p>\n<p>\nThe FDA\u2019s decision was informed by data from a two-part randomized, comparator-controlled, double-blind Phase 1\/2 study, V116-001 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04168190%3Fcond%3DA%2BPhase%2B1%252FPhase%2B2%252C%2BRandomized%252C%2BDouble-blind%2BStudy%2Bto%2BEvaluate%2Bthe%2BSafety%252C%2BTolerability%252C%2Band%2BImmunogenicity%2Bof%2Ba%2BPolyvalent%2BPneumococcal%2BConjugate%2BVaccine%2Bin%2BAdults%26draw%3D2%26rank%3D1&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=NCT04168190&amp;index=1&amp;md5=5c565be8d7fb5b4d7891f0493270afbd\">NCT04168190<\/a>), that assessed the safety, tolerability, and immunogenicity of a single dose of V116 in pneumococcal vaccine-na\u00efve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). Full results from the V116-001 study are planned for presentation at the upcoming International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in June.\n<\/p>\n<p>\n\u201cV116 is specifically designed to address strains of disease-causing pneumococcal bacteria that are most prevalent in adults, reflecting our population-specific approach to developing pneumococcal conjugate vaccines. V116 targets serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019<sup>1<\/sup> and it includes 8 serotypes not covered by currently licensed vaccines,\u201d said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. \u201cWe look forward to discussing the ongoing development of this investigational vaccine, including the approach for Phase 3 studies, with the FDA and other regulatory agencies.\u201d\n<\/p>\n<p>\nThe Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of products intended for serious or life-threatening conditions. To qualify for this designation, preliminary clinical evidence must indicate that the product may demonstrate substantial improvement over currently available options on at least one clinically significant endpoint. The benefits of this Breakthrough Therapy Designation include more intensive guidance from the FDA on an efficient development program, access to a scientific liaison to help accelerate review time and potential eligibility for Priority Review if relevant criteria are met.\n<\/p>\n<p>\n  <b>About Merck<\/b>\n<\/p>\n<p>\nAt Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world \u2013 and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=a2afbd5a7c47fbda4be608b8ebba071d\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=7eb8ae7d9da339807650f4b4530b2e0f\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=e598f9724e574fe4522682e0a4edf7a2\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=1fba248ad98dc1cc40a6701c2f8ff424\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=8209703568c0b9eac95e85264ce7e345\">YouTube<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=081a605d347cc3fd55f48016239b51a9\">LinkedIn<\/a>.\n<\/p>\n<p>\n  <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2021 and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52686629&amp;newsitemid=20220414005246&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=92142921c98bf5308a9a1ba114efa379\">www.sec.gov<\/a>).\n<\/p>\n<p>\n  <sup>1<\/sup>Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance (ABCs).\n<\/p>\n<p>\n  <img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n  <span class=\"bwct31415\"><\/span>\n<\/p>\n<p id=\"mmgallerylink\">\n  <span id=\"mmgallerylink-phrase\">View source version on <a href=\"http:\/\/businesswire.com\">businesswire.com<\/a>: <\/span><br \/>\n  <span id=\"mmgallerylink-link\"><br \/>\n    <a href=\"https:\/\/www.businesswire.com\/news\/home\/20220414005246\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20220414005246\/en\/<\/a><br \/>\n  <\/span>\n<\/p>\n<p>\nMedia Contacts:\n<\/p>\n<p>\nJulie Cunningham<br \/>\n<br \/>(617) 519-6264\n<\/p>\n<p>\nKimberly Petrillo<br \/>\n<br \/>(267) 742-2813\n<\/p>\n<p>\nInvestor Contacts:\n<\/p>\n<p>\nPeter Dannenbaum<br \/>\n<br \/>(908) 740-1037\n<\/p>\n<p>\nAlexis Constantine<br \/>\n<br \/>(908) 740-1051\n<\/p>\n<p>Source: Merck &amp; Co., Inc.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>V116 Designed to Target Serotypes that Account for 85% of all Invasive Pneumococcal Disease in Individuals Aged 65 and Over in the United States as of 20191 Phase 3 Clinical Trials for V116 to be Initiated in 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that V116, the company\u2019s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A\/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B\/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 clinical trials for V116 are to be initiated later this year. The FDA\u2019s decision was informed by data from a two-part randomized, comparator-controlled, double-blind Phase 1\/2 study, V116-001 ( NCT04168190 ), that assessed the safety,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,57],"class_list":["post-3597086","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-vaccine-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com\" \/>\n<meta property=\"og:description\" content=\"V116 Designed to Target Serotypes that Account for 85% of all Invasive Pneumococcal Disease in Individuals Aged 65 and Over in the United States as of 20191 Phase 3 Clinical Trials for V116 to be Initiated in 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that V116, the company\u2019s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A\/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B\/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 clinical trials for V116 are to be initiated later this year. The FDA\u2019s decision was informed by data from a two-part randomized, comparator-controlled, double-blind Phase 1\/2 study, V116-001 ( NCT04168190 ), that assessed the safety,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:39:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/\",\"name\":\"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-04-14T10:45:00+00:00\",\"dateModified\":\"2025-03-08T04:39:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com","og_description":"V116 Designed to Target Serotypes that Account for 85% of all Invasive Pneumococcal Disease in Individuals Aged 65 and Over in the United States as of 20191 Phase 3 Clinical Trials for V116 to be Initiated in 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that V116, the company\u2019s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A\/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B\/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 clinical trials for V116 are to be initiated later this year. The FDA\u2019s decision was informed by data from a two-part randomized, comparator-controlled, double-blind Phase 1\/2 study, V116-001 ( NCT04168190 ), that assessed the safety,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:39:57+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/","name":"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","datePublished":"2022-04-14T10:45:00+00:00","dateModified":"2025-03-08T04:39:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220414005246r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ed580012-2ea5-49cd-8a2d-594a401aa5c1","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_multimedia\/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg","size":"211320","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-U.S.-FDA-has-Granted-Breakthrough-Therapy-Designation-for-V116-the-Companys-Investigational-21-Valent-Pneumococcal-Co-TKB9V.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3597086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3597086\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=3597086"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=3597086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}